RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival

Cancer Research

Volumn 64, Issue 21, 2004, Pages 7962-7970

  Shinomiya, Nariyoshi ^a   Chong, Feng Gao ^a   Xie, Qian ^a   Gustafson, Margaret ^a   Waters, David J ^b,c   Zhang, Yu Wen ^a   Vande Woude, George F ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b PURDUE UNIVERSITY   (United States)

^c Gerald P Murphy Cancer Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; METHIONINE; RNA; SCATTER FACTOR; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BREAST TUMOR; CANCER INHIBITION; CANCER INVASION; CELL DEATH; CELL STRAIN 3T3; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; EMBRYO; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RNA INTERFERENCE; SARCOMA; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; DOGS; HUMANS; LIGANDS; MICE; MICE, INBRED BALB C; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; RECEPTORS, GROWTH FACTOR; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 7444231680     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1043     Document Type: Article

References (50)

1. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25.
2. Gherardi E, Stoker M. Hepatocyte growth factor-scatter factor: mitogen, motogen, and met. Cancer Cells (Cold Spring Harbor) 1991;3:227-32.
3. Birchmeier C, Gherardi E. Developmental roles of Hepatocyte growth factor/scatter factor and its receptor, the c-Met tyrosine kinase. Trends Cell Biol 1998;8:404-10.
4. Furge KA, Zhang YW, Vande Woude GF. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 2000;19:5582-9.
5. Park WS, Oh RR, Kim YS, et al. Absence of mutations in the kinase domain of the Met gene and frequent expression of Met and Hepatocyte growth factor/scatter factor protein in primary gastric carcinomas. APMIS 2000;108:195-200.
6. Morello S, Olivero M, Aimetti M, et al. MET receptor is overexpressed but not mutated in oral squamous cell carcinomas. J Cell Physiol 2001;189:285-90.
7. Wang R, Kobayashi R, Bishop JM. Cellular adherence elicits ligand-independent activation of the Met cell-surface receptor. Proc Natl Acad Sci USA 1996;93:8425-30.
8. Ponzetto C, Bardelli A, Zhen Z, et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994;77:261-71.
9. Zhang YW, Wang LM, Jove R, Vande Woude GF. Requirement of Stat3 signaling for Hepatocyte growth factor/scatter factor-Met mediated tumorigenesis. Oncogene 2002;21:217-26.
10. Xiao GH, Jeffers M, Bellacosa A, et al. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci USA 2001;98:247-52.
11. Fan S, Ma YX, Gao M, et al. The multisubstrate adapter Gab1 regulates hepatocyte growth factor (scatter factor)-c-Met signaling for cell survival and DNA repair. Mol Cell Biol 2001;21:4968-84.
12. Harvey P, Clark IM, Jaurand MC, Warn RM, Edwards DR. Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases. Br J Cancer 2000;83:1147-53.
13. Kermorgant S, Aparicio T, Dessirier V, Lewin MJ, Lehy T. Hepatocyte growth factor induces colonic cancer cell invasiveness via enhanced motility and protease overproduction. Evidence for PI3 kinase and PKC involvement. Carcinogenesis (Lond) 2001;22:1035-42.
14. Rosen EM, Lamszus K, Laterra J, et al. HGF/SF in angiogenesis. CIBA Found Symp 1997;212: 215-26; discussion 27-9.
15. Tomita N, Morishita R, Taniyama Y, et al. Angiogenic property of hepatocyte growth factor is dependent on upregulation of essential transcription factor for angiogenesis, ets-1. Circulation 2003;107:1411-7.
16. Zhang YW, Su Y, Volpert OV, Vande Woude GF. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA 2003;100:12718-23.
17. Cao B, Su Y, Oskarsson M, et al. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (Hepatocyte growth factor/scatter factor) display antitumor activity in animal models. Proc Natl Acad Sci USA 2001;98:7443-8.
18. Kitamura S, Kondo S, Shinomura Y, et al. Met/HGF receptor modulates bcl-w expression and inhibits apoptosis in human colorectal cancers. Br J Cancer 2000;83:668-73.
19. Firon M, Shaharabany M, Altstock RT, et al. Dominant negative Met reduces tumorigenicity-metastasis and increases tubule formation in mammary cells. Oncogene 2000;19:2386-97.
20. Furge KA, Kiewlich D, Le P, et al. Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase. Proc Natl Acad Sci USA 2001;98:10722-7.
21. Abounader R, Ranganathan S, Lal B, et al. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J Natl Cancer Inst (Bethesda) 1999;91:1548-56.
22. Abounader R, Lal B, Luddy C, et al. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J 2002;16:108-10.
23. Christensen JG, Schreck R, Burrows J, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003;63:7345-55.
24. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (Lond) 2001;411:494-8.
25. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (Lond) 1998;391:806-11.
26. Tuschl T, Zamore PD, Lehmann R, Bartel DP, Sharp PA. Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev 1999;13:3191-7.
27. Lin SL, Sukasweang S, Chuong CM, Rasheed S, Ying SY. D-RNAi (messenger RNA-antisense DNA interference) as a novel defense system against cancer and viral infections. Curr Cancer Drug Targets 2001;1:241-7.
28. Sui G, Soohoo C, Affar el B, et al. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA 2002;99:5515-20.
29. McCaffrey AP, Meuse L, Pham TT, et al. RNA interference in adult mice. Nature (Lond) 2002;418:38-9.
30. Lee NS, Dohjima T, Bauer G, et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 2002;20:500-5.
31. Barton GM, Medzhitov R. Retroviral delivery of small interfering RNA into primary cells. Proc Natl Acad Sci USA 2002;99:14943-5.
32. Paddison PJ, Hannon GJ. RNA interference: the new somatic cell genetics? Cancer Cell 2002;2:17-23.
33. Rubinson DA, Dillon CP, Kwiatkowski AV, et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 2003;33:401-6.
34. Tiscornia G, Singer O, Ikawa M, Verma IM. A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc Natl Acad Sci USA 2003;100:1844-8.
35. Xia H, Mao Q, Paulson HL, Davidson BL. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002;20:1006-10.
36. Yu JY, DeRuiter SL, Turner DL. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci USA 2002;99:6047-52.
37. Rong S, Bodescot M, Blair D, et al. Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol Cell Biol 1992;12:5152-8.
38. Graziani A, Gramaglia D, Cantley LC, Comoglio PM. The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase. J Biol Chem 1991;266:22087-90.
39. Coltella N, Manara MC, Cerisano V, et al. Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. FASEB J 2003;17:1162-4.
40. Song E, Lee SK, Dykxhoorn DM, et al. Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. J Virol 2003;77:7174-81.
41. Nemerow GR. Cell receptors involved in adenovirus entry. Virology 2000;274:1-4.
42. Pearson AS, Koch PE, Atkinson N, et al. Factors limiting adenovirus-mediated gene transfer into human lung and pancreatic cancer cell lines. Clin Cancer Res 1999;5:4208-13.
43. Gmyrek GA, Walburg M, Webb CP, et al. Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. Am J Pathol 2001;159:579-90.
44. Huh CG, Factor VM, Sanchez A, et al. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci USA 2004;101:4477-82.
45. Bowers DC, Fan S, Walter KA, et al. Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways. Cancer Res 2000;60:4277-83.
46. Takeuchi K, Ito F. Suppression of adriamycin-induced apoptosis by sustained activation of the phosphatidylinositol-3′-OH kinase-Akt pathway. J Biol Chem 2004;279:892-900.
47. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003;22:309-25.
48. Shinomiya N, Vande Woude GF. Suppression of met expression: a possible cancer treatment. Commentary re: S. J. Kim et al., reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model. Clin. Cancer Res. 14: 5161-70, 2003. Clin Cancer Res 2003;9:5085-90.
49. Maemondo M, Narumi K, Saijo Y, et al. Targeting angiogenesis and HGF function using an adenoviral vector expressing the HGF antagonist NK4 for cancer therapy. Mol Ther 2002;5:177-85.
50. Herynk MH, Stoeltzing O, Reinmuth N, et al. Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells. Cancer Res 2003;63:2990-6.